ALACD

ALACD (Associate LncRNAs with Anti-Cancer Drugs) is a computational tool that predicts associations between long noncoding RNAs (lncRNAs) and anti-cancer drugs. It uses a bilevel optimization model to identify genes coexpressed with lncRNAs while matching the drug-gene signatures. By leveraging the target gene information of small molecules, ALACD helps understand the mechanisms of action of lncRNAs and their roles in cancer.

The Authors applied to 10 cancer types from The Cancer Genome Atlas (TCGA), identifying cancer type-specific lncRNAs and associated drugs. These lncRNAs show significant differential expression in cancer patients and are related to cancer development. The identified lncRNAs and drug-lncRNA associations may provide alternative targets for cancer treatment and potential prognostic biomarkers.

Topic

Functional, regulatory and non-coding RNA;Small molecules;Oncology;Gene transcripts;Gene expression

Detail

  • Operation: Imputation;Differential gene expression analysis;Expression analysis

  • Software interface: Command-line user interface

  • Language: R

  • License: Not stated

  • Cost: Free of charge

  • Version name: -

  • Credit: National Natural Science Foundation of China, Qinghai Sciences and Technology Department, Chinese Academy of Sciences, and National Key Research and Development Program of China.

  • Input: -

  • Output: -

  • Contact: Yongcui Wang ycwang@nwipb.cas.cn, Yong Wang ywang@amss.ac.cn

  • Collection: -

  • Maturity: -

Publications

  • Associating lncRNAs with small molecules via bilevel optimization reveals cancer-related lncRNAs.
  • Wang Y, et al. Associating lncRNAs with small molecules via bilevel optimization reveals cancer-related lncRNAs. Associating lncRNAs with small molecules via bilevel optimization reveals cancer-related lncRNAs. 2019; 15:e1007540. doi: 10.1371/journal.pcbi.1007540
  • https://doi.org/10.1371/JOURNAL.PCBI.1007540
  • PMID: 31877126
  • PMC: PMC6948815

Download and documentation

< Back to DB search